0001140361-23-012511.txt : 20230320 0001140361-23-012511.hdr.sgml : 20230320 20230320135845 ACCESSION NUMBER: 0001140361-23-012511 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230320 DATE AS OF CHANGE: 20230320 EFFECTIVENESS DATE: 20230320 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Myovant Sciences Ltd. CENTRAL INDEX KEY: 0001679082 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: CA FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 15-12G SEC ACT: 1934 Act SEC FILE NUMBER: 001-37929 FILM NUMBER: 23745848 BUSINESS ADDRESS: STREET 1: SUITE 1, 3RD FLOOR STREET 2: 11-12 ST. JAMES SQUARE CITY: LONDON STATE: X0 ZIP: SW1Y 4LB BUSINESS PHONE: 44 207-400-3351 MAIL ADDRESS: STREET 1: SUITE 1, 3RD FLOOR STREET 2: 11-12 ST. JAMES SQUARE CITY: LONDON STATE: X0 ZIP: SW1Y 4LB 15-12G 1 ny20008100x3_15-12g.htm 15-12G

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 15


CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-37929


MYOVANT SCIENCES LTD.
(Exact name of registrant as specified in its charter)


7th Floor
50 Broadway
London
SW1H 0DB
United Kingdom
+44 207 400 3351
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Shares, par value $0.000017727 per share
(Title of each class of securities covered by this Form)

None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 
Rule 12g-4(a)(1)
☒
 
Rule 12g-4(a)(2)
☐
 
Rule 12h-3(b)(1)(i)
☒
 
Rule 12h-3(b)(1)(ii)
☐
 
Rule 15d-6
☐
 
Rule 15d-22(b)
☐

Approximate number of holders of record as of the certification or notice date: 1

Pursuant to the requirements of the Securities Exchange Act of 1934, Myovant Sciences Ltd. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: March 20, 2023
MYOVANT SCIENCES LTD.
     
     
 
By:
/s/ Matthew Lang
 
Name:
Matthew Lang
 
Title:
General Counsel